Coronavirus: This scanning electron microscope image shows SARS-CoV-2 (round blue objects) emerging from the surface of cells cultured in the lab. Credit: NIAID-RML.

Visit our COVID-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Australian biopharmaceutical firm Beroni Group has partnered with Tianjin University in China to develop targeted treatment and quick detection technique for COVID-19.

To develop the medical solution, the partners will use nanobody-based technology.

Compared to standard antibody, nanobody is said to be more stable, enables better screening / isolation and has high absorption rates with low immunogenicity.

Beroni Group chairman and CEO Jacky Zhang said: “We are pleased to be working with Tianjin University to develop a novel medical solution for the detection and treatment of COVID-19.

Beroni Group has an international network of scientists with the expertise in prevention, detection and control of infectious diseases. Given the urgency of the COVID-19 epidemic, we will work with regulatory bodies to accelerate research and advance studies into clinical trials.”

The researchers working on the project will leverage computer simulation to predict the virus’ structure with various neutralising antibodies.

Also, the technology will be used to identify the crystal structure of nano-antibodies and antigens, as well as understand the structural binding between antigens.